PE20070854A1 - Compuestos heterociclos como agonistas del receptor de acido nicotinico - Google Patents

Compuestos heterociclos como agonistas del receptor de acido nicotinico

Info

Publication number
PE20070854A1
PE20070854A1 PE2007000050A PE2007000050A PE20070854A1 PE 20070854 A1 PE20070854 A1 PE 20070854A1 PE 2007000050 A PE2007000050 A PE 2007000050A PE 2007000050 A PE2007000050 A PE 2007000050A PE 20070854 A1 PE20070854 A1 PE 20070854A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
agonists
nicotinic acid
acid receptor
Prior art date
Application number
PE2007000050A
Other languages
English (en)
Inventor
Anandan Palani
Dong Xiao
Xianhai Huang
Xiao Chen
Jun Quin
Ying R Huang
Robert G Aslanian
Zhidan Liu
Sylvia Degrado
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070854A1 publication Critical patent/PE20070854A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 ES H, R4, HALOALQUILO(C1-C20), ALQUILEN-R4, ALQUENILO(C2-C15), ENTRE OTROS, DONDE R4 ES CICLOALQUILO(C3-C10) OPCIONALMENTE SUSTITUIDO CON X1, EN DONDE X1 ES HALOGENO, ALQUILO(C1-C20), -O-ALQUILO(C1-C20), OH, ENTRE OTROS; R2 ES ALQUILO(C1-C20), HALOALQUILO(C1-C20), ALQUILEN-R5, ENTRE OTROS, DONDE R5 ES ARILO(C6-C14) OPCIONALMENTE SUSTITUIDO CON X2, EN DONDE X2 ES HALOGENO, ALQUILO(C1-C20), -O-ALQUILO(C1-C20), OH, ENTRE OTROS; R3 ES ALQUILO(C1-C20), HALOALQUILO(C1-C20), ALQUILEN-R5, ENTRE OTROS; Y ES O U N(R10) DONDE R10 ES -C(O)-ALQUILO(C1-C20), -C(O)-R5, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (a), (b), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE ACIDO NICOTINICO SIENDO UTILES PARA EL TRATAMIENTO DEL SINDROME METABOLICO, DISLIPIDEMIA, CANCER, DIABETES, ENFERMEDAD DEL HIGADO GRASO NO ALCOHOLICO
PE2007000050A 2006-01-20 2007-01-17 Compuestos heterociclos como agonistas del receptor de acido nicotinico PE20070854A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76055506P 2006-01-20 2006-01-20

Publications (1)

Publication Number Publication Date
PE20070854A1 true PE20070854A1 (es) 2007-09-10

Family

ID=38190797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000050A PE20070854A1 (es) 2006-01-20 2007-01-17 Compuestos heterociclos como agonistas del receptor de acido nicotinico

Country Status (14)

Country Link
US (1) US7763623B2 (es)
EP (1) EP1976854A2 (es)
JP (1) JP2009525961A (es)
KR (1) KR20080091814A (es)
CN (1) CN101400682A (es)
AR (1) AR059056A1 (es)
AU (1) AU2007208478A1 (es)
CA (1) CA2637717A1 (es)
IL (1) IL192907A0 (es)
MX (1) MX2008009413A (es)
PE (1) PE20070854A1 (es)
TW (1) TW200738729A (es)
WO (1) WO2007087204A2 (es)
ZA (1) ZA200806293B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4975739B2 (ja) * 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
AR059056A1 (es) 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
CA2766696A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
TW201309639A (zh) 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為ｇｐｒ１１９促效劑之肟衍生物
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
WO2018053587A1 (en) * 2016-09-21 2018-03-29 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2826580A (en) 1958-03-11 Derivatives of y
DD263891A3 (de) 1986-12-23 1989-01-18 Dresden Arzneimittel Verbessertes verfahren zur herstellung von 2,4,6,8-tetrahydroxy-yrimido[5,4-d] pyrimidin und seinen salzen
DD265760A3 (de) 1987-05-25 1989-03-15 Dresden Arzneimittel Verfahren zur herstellung von 2,4,6,8-tetrachlorpyrimido-[5,4-d]pyrimidin
DE19624154A1 (de) 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US20040137563A9 (en) 1998-10-13 2004-07-15 Ruoping Chen Endogenous and non-endogenous versions of human G protein-coupled receptors
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
CA2469316A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
JP3988830B2 (ja) * 2002-11-22 2007-10-10 日本たばこ産業株式会社 縮合二環式窒素含有複素環
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
CA2556073C (en) * 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20050251869A1 (en) 2004-05-04 2005-11-10 Tian-Quan Cai Animal model for raising HDL-cholesterol with niacin
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
KR20070070231A (ko) 2004-10-22 2007-07-03 스미스클라인 비참 코포레이션 Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
CN101146798A (zh) 2005-01-21 2008-03-19 詹森药业有限公司 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物
AU2006214286A1 (en) 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
JP4975739B2 (ja) 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20090117559A1 (en) 2005-08-10 2009-05-07 Liaw Chen W Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist
US8691498B2 (en) 2005-09-02 2014-04-08 Arena Pharmaceuticals, Inc. Methods of screening for a compound that reduces atherogenesis
AR059056A1 (es) 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
EP2158203A2 (en) 2007-04-13 2010-03-03 Schering Corporation Pyrimidinedione derivatives and use thereof

Also Published As

Publication number Publication date
CN101400682A (zh) 2009-04-01
JP2009525961A (ja) 2009-07-16
KR20080091814A (ko) 2008-10-14
US20070173495A1 (en) 2007-07-26
TW200738729A (en) 2007-10-16
AU2007208478A1 (en) 2007-08-02
US7763623B2 (en) 2010-07-27
ZA200806293B (en) 2009-07-29
WO2007087204A3 (en) 2007-09-13
EP1976854A2 (en) 2008-10-08
IL192907A0 (en) 2009-02-11
WO2007087204A2 (en) 2007-08-02
AR059056A1 (es) 2008-03-12
CA2637717A1 (en) 2007-08-02
MX2008009413A (es) 2008-10-01

Similar Documents

Publication Publication Date Title
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
AR061924A1 (es) Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20191528A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20060857A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20121509A1 (es) Compuestos de triazolopiridinas como inhibidores de quinasa mps-1
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
PE20160874A1 (es) Compuestos quimicos
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20061099A1 (es) Compuestos de piridil acido acetico como inhibidores de peptidasa
PE20141691A1 (es) Compuestos con actividad nematicida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed